Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: bispecifc antibodies - I-Mab Biopharma

Next Previous
Drug Profile

Research programme: bispecifc antibodies - I-Mab Biopharma

Alternative Names: PD-L1 x 4-1BB bispecific antibody; PD-L1 x B7-H3 bispecific antibody; PD-L1 x CD47 bispecific antibody; PD-L1 x CD73 bispecific antibody; PD-L1 x IL-7 bispecific antibody

Latest Information Update: 28 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator I-MAB Biopharma
  • Developer I-MAB Biopharma; TRACON Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 25 Apr 2023 I-Mab terminates the agreement with TRACON Pharmaceuticals
  • 27 Feb 2020 TRACON Pharmaceuticals intends to submit IND application to the US FDA for bispecific antibodies for Cancer in second half of 2020

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top